PositiveID to Use PCR Technology as Part of Shared Defense Contract with Leidos | GenomeWeb

NEW YORK (GenomeWeb) – Leidos and partner PositiveID have been awarded a contract from the US Defense Threat Reduction Agency (DTRA) to develop detection technologies for potential weapons of mass destruction.

Leidos is one of seven contractors eligible to compete for task orders under the DTRA contract, PositiveID said today. The multiple-award indefinite delivery/indefinite quantity contract has a five-year base period of performance, and if all options are exercised, it is valued at $4 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.